• Je něco špatně v tomto záznamu ?

Azolová rezistencia kvasiniek rodu Candida
[Azole resistance in candida yeasts]

Zuzana Malinovská, Eva Čonková, Peter Váczi, Martina Proškovcová

. 2022 ; 116 (8) : 494−500.

Jazyk slovenština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc23007944

Systemic fungal diseases and antifungal resistance represent a serious problem in human medicine and con-tribute to increased patient mortality. The most common causes of these diseases are opportunistic yeasts of the genus Candida. C. albicansis considered to be the main pathogen, together with C. glabrata, C. tropicalis, C. par-apsilosis, and C.krusei. Azole antifungals predominate in the treatment of the systemic mycoses. For antifungal re-sistance in Candidaspp. some genes and their mutations are responsible, the genes ERG11, CDR1, CDR2and MDR1being considered the most important. The main target of azole antifungals is the process of ergosterol syn-thesis. Due to ergosterol crucial functions and its unique structural properties, the synthesis of ergosterol and its individual steps represent the target of most clinically available antifungals. The biofilm appears to be a signifi-cant virulence factor of the yeast Candidaspp. It allows hematogenous dissemination of cells, prevents the effect of antifungals on all cells during treatment and leads to a high level of antimicrobial resistance. The antifungal re-sistance in candidiasis often has a multifactorial origin, which must be considered in the treatment of systemic mycoses and in the development of new antifungals.

Azole resistance in candida yeasts

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc23007944
003      
CZ-PrNML
005      
20240220150019.0
007      
ta
008      
230616s2022 xr a f 000 0|slo||
009      
AR
024    7_
$a 10.54779/chl20220494 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a slo $b eng
044    __
$a xr
100    1_
$a Malinovská, Zuzana $7 xx0302986 $u Katedra farmakológie a toxikológie, Univerzita veterinár-skeho lekárstva a farmácie v Košiciach, Slovenská republika
245    10
$a Azolová rezistencia kvasiniek rodu Candida / $c Zuzana Malinovská, Eva Čonková, Peter Váczi, Martina Proškovcová
246    31
$a Azole resistance in candida yeasts
504    __
$a Literatura
520    3_
$a Systemic fungal diseases and antifungal resistance represent a serious problem in human medicine and con-tribute to increased patient mortality. The most common causes of these diseases are opportunistic yeasts of the genus Candida. C. albicansis considered to be the main pathogen, together with C. glabrata, C. tropicalis, C. par-apsilosis, and C.krusei. Azole antifungals predominate in the treatment of the systemic mycoses. For antifungal re-sistance in Candidaspp. some genes and their mutations are responsible, the genes ERG11, CDR1, CDR2and MDR1being considered the most important. The main target of azole antifungals is the process of ergosterol syn-thesis. Due to ergosterol crucial functions and its unique structural properties, the synthesis of ergosterol and its individual steps represent the target of most clinically available antifungals. The biofilm appears to be a signifi-cant virulence factor of the yeast Candidaspp. It allows hematogenous dissemination of cells, prevents the effect of antifungals on all cells during treatment and leads to a high level of antimicrobial resistance. The antifungal re-sistance in candidiasis often has a multifactorial origin, which must be considered in the treatment of systemic mycoses and in the development of new antifungals.
650    17
$a kandidóza $x farmakoterapie $x mikrobiologie $7 D002177 $2 czmesh
650    _7
$a Candida $x patogenita $x účinky léků $7 D002175 $2 czmesh
650    _7
$a faktory virulence $7 D037521 $2 czmesh
650    _7
$a biofilmy $x účinky léků $7 D018441 $2 czmesh
650    _7
$a ergosterol $x biosyntéza $7 D004875 $2 czmesh
650    _7
$a antifungální látky $x chemie $x farmakologie $x terapeutické užití $7 D000935 $2 czmesh
650    _7
$a azoly $x farmakologie $x terapeutické užití $7 D001393 $2 czmesh
650    _7
$a flukonazol $x farmakologie $x terapeutické užití $7 D015725 $2 czmesh
650    _7
$a itrakonazol $x farmakologie $x terapeutické užití $7 D017964 $2 czmesh
650    _7
$a vorikonazol $x farmakologie $x terapeutické užití $7 D065819 $2 czmesh
650    _7
$a fungální léková rezistence $7 D025141 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
700    1_
$a Čonková, Eva $7 xx0149289 $u Katedra farmakológie a toxikológie, Univerzita veterinár-skeho lekárstva a farmácie v Košiciach, Slovenská republika
700    1_
$a Váczi, Peter $7 xx0302974 $u Katedra farmakológie a toxikológie, Univerzita veterinár-skeho lekárstva a farmácie v Košiciach, Slovenská republika
700    1_
$a Proškovcová, Martina $7 xx0302987 $u Katedra farmakológie a toxikológie, Univerzita veterinár-skeho lekárstva a farmácie v Košiciach, Slovenská republika
773    0_
$t Chemické listy $x 0009-2770 $g Roč. 116, č. 8 (2022), s. 494−500 $w MED00011010
856    41
$u http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/Archives $y stránka časopisu
910    __
$a ABA008 $b B 1918 $c 395 $y p $z 0
990    __
$a 20230531121729 $b ABA008
991    __
$a 20240220150016 $b ABA008
999    __
$a ok $b bmc $g 1945782 $s 1194183
BAS    __
$a 3
BMC    __
$a 2022 $b 116 $c 8 $d 494−500 $i 0009-2770 $m Chemické listy $x MED00011010
LZP    __
$c NLK183 $d 20231014 $a NLK 2023-05/iš

Najít záznam

Citační ukazatele

Možnosti archivace